Overview

Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies have implied a possible role of adenosine. The purpose of this study is to determine if the caffeine-antagonist is effective in reducing dyspnea related to ticagrelor.
Phase:
Phase 2
Details
Lead Sponsor:
Uppsala University
Collaborator:
AstraZeneca
Treatments:
Caffeine
Ticagrelor